ABSTRACT Background: To understand the effect of selenium intake on health, it is important to identify sensitive and population-specific biomarkers of selenium status. Objective: The objective of this systematic review was to assess the usefulness of biomarkers of selenium status in humans. Design: The methods included a structured search strategy on Ovid MEDLINE, EMBASE (Ovid), and Cochrane databases; formal inclusion and exclusion criteria; data extraction into an Access database; validity assessment; and meta-analysis. Results: The data from 18 selenium supplementation studies (of which 9 were randomized controlled trials and 1 was considered to be at low risk of bias) indicate that plasma, erythrocyte, and whole-blood selenium, plasma selenoprotein P, and plasma, platelet, and whole-blood glutathione peroxidase activity respond to changes in selenium intake. Although there is a substantial body of data for plasma selenium, more large, high-quality, randomized controlled trials are needed for this biomarker, as well as for the other biomarkers, to explore the reasons for heterogeneity in response to selenium supplementation. There was insufficient evidence to assess the usefulness of other potential biomarkers of selenium status, including urinary selenium, plasma triiodothyroxine:thyroxine ratio, plasma thyroxine, plasma total homocysteine, hair and toenail selenium, erythrocyte, and muscle glutathione peroxidase activity. Conclusions: For all potentially useful biomarkers, more information is needed to evaluate their strengths and limitations in different population groups, including the effects of varying intakes, the duration of intervention, baseline selenium status, and possible confounding effects of genotype.
INTRODUCTION
Dietary recommendations for selenium are currently based on the quantity of selenium required to optimize the activity of glutathione peroxidase (GPx), an enzyme involved in antioxidant defense. Selenium is found predominantly as selenomethionine and selenocysteine in foods such as bread, cereals, nuts, meat, fish, and other seafood, but the amount and the type of selenium in foods varies greatly and depends on the soil selenium content and composition (1, 2) . Because the distribution of selenium in soil varies, there are regions in the world where the recommended intakes are exceeded [including regions of China (3) and the United States (4) ] and regions where the recommended intakes are not met [including large parts of Europe (4, 5) ].
Clinical signs of selenium deficiency include Keshan disease, a cardiomyopathy mainly affecting young children and women of childbearing age, which is apparent in areas of China in populations with particularly low intakes (,15 lg/d) (6) . Selenium status has also been inversely associated with other health problems, including cancer, infertility, impaired immune function (7) , and mortality (8, 9) . However, as there is a relatively narrow range of selenium intake between toxicity (.900 lg/d) and deficiency (,30 lg/d), functional biomarkers are critical for estimating intakes that are associated with risks and benefits to health.
Selenium is incorporated into 25 selenoproteins (10) with activities including protection against lipid peroxidation, thyroid hormone metabolism (7), T cell immunity (11) , and modulation of inflammatory response (12) . The most abundant selenoproteins in blood are selenoprotein P, which accounts for '50% of plasma selenium (13, 14) , and GPx, which accounts for 10-30% of plasma selenium (14) .
For this systematic review, we considered the forms of selenium employed in supplementation studies that would represent dietary selenium. Selenomethionine is an organic form of selenium that is widely found in foods and in selenium-enriched yeast sold as selenium supplements, whereas inorganic selenium, such as selenite, is not naturally present in the diet and is metabolized differently (15) . For this reason, studies involving supplementation with selenite were not accepted for this review. In relation to the minimum time period required to observe a change in selenium status, it has been shown that plasma selenoprotein P attained a maximal response after 4 wk in individuals supplemented with 200 lg Se/d as selenium-enriched yeast (16) , whereas platelet GPx reached a plateau at 45 d ('6 wk) and urinary selenium at 30-60 d in individuals supplemented with 100 lg Se/d as selenomethionine (17) . Plasma selenium can take longer to reach a plateau and was still rising 60 d from the start of an intervention in which individuals were given 100 lg Se/d (17) . We therefore selected 6 wk as the minimum period for intervention because we considered it sufficient for changes to occur in most recognized indexes of selenium status, even if they have not yet reached a plateau.
The aim of this review was to assess the usefulness of commonly employed biomarkers of selenium status in humans. The primary question to be answered by this review was: Which measures (biomarkers) of selenium status appropriately reflect change in selenium status over !6 wk?
METHODS
A general or main methodology was developed for this series of reviews (18) , and specific methodologies used for this review that focus on differences from the main methodology are briefly described below.
Types of study
To be included, a study needed to meet all of the following criteria: 1) a controlled trial of selenium (including supplementation with selenomethionine or selenium-enriched yeast or selenium depletion); 2) reported selenium status at baseline and after supplementation or depletion; 3) supplementation or depletion lasting for !6 wk; 4) healthy human adults as participants (excluded when participants were elderly, pregnant, or postmenopausal women, unless stated otherwise); 5) written in English; and 6) data presented in a usable format.
Search strategy

Electronic searches
We searched Ovid MEDLINE (www.ovid.com), EMBASE (Ovid; www.ovid.com), and the Cochrane Library CENTRAL (www.thecochranelibrary.com) databases from inception to September 2007 for selenium intervention studies by using text terms with appropriate truncation and relevant indexing terms. The general structure of the search was ''selenomethionine OR yeast OR organoselenium compounds'' and ''intervention OR supplementation OR depletion'' and ''humans.'' The full Ovid MEDLINE search strategy can be found in Supplemental Table  S1 under ''Supplemental data'' in the online issue. This strategy was adapted for the other databases.
Reference search
An additional Ovid MEDLINE search was conducted for reviews of the methods of selenium status assessment. Twelve reviews were collected in full text, and their reference lists were checked (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . Intervention studies that had not been already assessed for inclusion were collected. Further relevant studies were also identified via reference lists of included studies; and 2 experts in the field were asked whether there were any other studies that should be included.
Data collection
Titles and abstracts were screened for inclusion by a single reviewer. The full text of all collected articles was screened for inclusion by using an inclusion and exclusion form by a single reviewer. For each step, a duplicate assessment of 10% by a second reviewer was conducted, and when the 2 reviewers disagreed, the study was discussed and a consensus decision reached.
Data for each included study were extracted into a Microsoft Access (Microsoft Corp, Redmond, WA) database file by a single reviewer with independent duplicate assessment of a sample of 10% by a second reviewer. The data extraction form in Access was tested on 2 articles by each of the reviewers and discussed with the review team before beginning full data extraction. Data extraction was as discussed in the main methodology article (18) .
Further information was requested, where possible, from the study authors if the data format rendered extraction difficult (15, 31, 32) . However, in many cases, certain assumptions had to be made to use the available data. Many studies reported outcome data in graphical format so data were taken from tables preferentially, from the text where tables were not available, and from graphs (enlarged and using a ruler) only where necessary. In graphs, where bars representing the SD or SE overlapped so that variance was unclear, the largest realistic SD or SE for each point was used (as a conservative estimate, tending to reduce the importance of the data in meta-analysis rather than to overstate it). In many instances, the numbers of participants in each group and at each time point were unclear, and here we assumed that all participants remained in the study and were included in the group analyses unless otherwise stated. In studies in which variance data were incompletely reported, it was occasionally necessary to use the largest of a stated range of SDs or, where outcome SDs were not reported, assume that the baseline SD also applied to the outcome data.
Data synthesis
Primary and secondary measures of interest were as stated in the main methodology paper, and data were subsequently synthesized as described (18) . Briefly, the primary measures of interest were the biomarkers reflecting selenium status after 6 wk intervention, and the secondary measures were how these biomarkers are influenced by other factors, such as methods of analysis, study design, length of intervention, supplemental dose, population subgroups, sex, age, etc.
RESULTS
The flow diagram for this review appears in Figure 1 . Of the 601 titles and abstracts screened after electronic and bibliographic searches, 169 appeared to be potentially relevant and 168 were collected as full-text articles to be assessed for inclusion (one could not be located). After excluding 145 articles for various reasons (see Figure 1 ), 18 studies (15, 17, 31-46)-reported in 23 publications-fulfilled the inclusion criteria and were included in this review. Nine of the 18 included studies were randomized, but none described the method of randomization. Details of the included studies and their validity are documented in Table 1 and Table 2 . One study appeared to be at low risk of bias in that it was randomized, specified dropouts and reasons for dropouts, ensured that supplements were taken under staff supervision, and independently verified the dose of 10 tablets from each batch (32) .
Biomarker efficacy
The results of the assessments of the efficacy of each biomarker are shown in Table 3 .
Plasma selenium
Nine of the 14 studies that measured plasma selenium were randomized (15, 31, 32, 34, (42) (43) (44) (45) (46) . These studies included 512 participants with between 6 (17) and 86 participants per arm (46) . Overall, the effect of selenium supplementation was to significantly increase plasma selenium [weighted mean difference (WMD): 0.90 lmol/L; 95% CI: 0.67, 1.14; 14 studies, 512 participants; P heterogeneity , 0.00001; I 2 : 97%], although there was significant heterogeneity between the results of the different studies ( Figure 2 ). This heterogeneity was not explained by subgrouping by study methodology, supplement type, dose, baseline status, assay type, duration of supplementation, or sex ( Table 4) . The results were statistically significant for all subgroups, although for some there were insufficient studies or participants to declare the marker useful ( Table 4 ). The one study at low risk of bias suggested a result similar to the pooled studies (32; 0.89 lmol/L; 95% CI: 0.76, 1.02; 29 participants).
Plasma selenium is clearly a useful biomarker of selenium status in many different situations, but further research is needed to assess the source of heterogeneous responses to supplementation.
Erythrocyte selenium
Six supplementation studies assessed erythrocyte selenium, which included 137 participants, with between 6 (17) and 20 participants per arm (38) . Only one of the 6 studies that measured erythrocyte selenium was randomized (45) . None of the studies were at low risk of bias ( Table 2) . Four of the studies were carried out in Europe (one in a low-selenium area of Finland and one in the same area 2 y after supplementation of fertilizers with selenium), one in China (in a low-selenium area), and one in New Zealand. Of the 6 studies, 2 report erythrocyte selenium in micromoles per liter and 4 in nanomoles per gram hemoglobin, so unfortunately they could not be combined in a single meta-analysis. However, by using both units, the effect of selenium supplementation was statistically significant (Figure 3 ). With only 4 included studies available, subgrouping would not produce meaningful results, so we could not explore the reasons for this heterogeneity.
The data suggest that erythrocyte selenium is likely to be a useful biomarker of selenium status, but more high-quality studies are needed to confirm this and to explore the reasons for the observed heterogeneity of response. (Continued)
REVIEW OF BIOMARKERS OF SELENIUM STATUS
Whole-blood selenium
Four supplementation studies that included 85 participants, with between 10 (31, 42, 45) and 12 participants per arm, assessed whole-blood selenium (40) . None of the included studies were considered to be at low risk of bias (Table 2) . One study was carried out in Europe and 3 in New Zealand. Two studies gave selenium-enriched yeast and the others selenomethionine. Duration was from 12 to 32 wk, and doses were 40, 100, or 200 lg/d.
Meta-analysis of the 4 studies suggested a statistically significant effect of supplementation on whole-blood selenium (WMD: 1.07 lmol/L; 95% CI: 0.39, 1.76; 85 participants; P heterogeneity , 0.00001; I 2 : 99%) (Figure 4) , but again there were insufficient studies for subgrouping to be usefully employed to explore the sources of the heterogeneity. However, it is notable that the study that chose participants for their lowselenium status showed the greatest change in whole-blood selenium (42) .
The data suggest that whole-blood selenium is likely to be a useful biomarker of selenium status, but more high-quality studies are needed to explore the reasons for the observed heterogeneity of response.
Urinary selenium
Four supplementation studies assessed urinary selenium. These studies included 67 participants, with between 5 (33) and 12 participants per arm (45) . The validity of the included studies is given in Table 2 , although none of the studies were considered to be at low risk of bias.
Urinary selenium was measured as micromoles per day in 2 studies and as micromoles per gram creatinine in the other 2, so they could not be combined in one meta-analysis. However, meta-analysis with both sets of units showed statistically significant effects of selenium supplementation on urinary selenium (WMD: 1.20 lmol/d; 95% CI: 0.88, 1.51; 31 participants; The data from all 4 studies suggested that urinary selenium may be a useful marker of selenium status, but more studies are needed to confirm this and to explore the reasons for the observed heterogeneity. 
GPx activity: plasma
Eight supplementation studies assessed plasma GPx activity with a total of 319 participants, with between 6 (15, 17) and 86 participants per arm (46) . Only one study (32) was assessed as being at low risk of bias (Table 2) . Three studies were carried out in Europe, 3 in New Zealand, one in the United States, and one in China. Five studies gave selenium-enriched yeast and the others selenomethionine (one study had arms giving both); only the data from the selenomethionine supplementation were used in these analyses. Duration was from 8 to 32 wk, and doses were from 40 to 507 lg/d.
Plasma Figure 5A ). Due to a paucity of studies, it was not helpful to use subgrouping to explain heterogeneity.
Pooling with the greatest number of participants suggests that plasma GPx activity is a useful biomarker of selenium status, but further research is needed to clarify in which groups and under what circumstances it is predictive and to pinpoint the sources of heterogeneity seen within the pooling.
GPx activity: other blood compartments
Five supplementation studies that included 109 participants assessed platelet GPx activity; participant numbers of these studies varied between 6 (17) and 19 subjects per arm (37) . None of the studies were considered to be at low risk of bias ( Table 2 ). The participants in 2 of the included studies were described as ''healthy,'' a low-selenium-status population in New Zealand was used in one study, healthy middle-aged men with naturally low plasma selenium in Finland in another, and the final study consisted of residents of a previously low-selenium area that had had selenium added to fertilizers. Four of the included studies measured platelet GPx activity in units per gram protein, and one in nmol NADPH oxidized Á min 21 Á 10 10 cells.
Pooling the 4 studies showed a statistically significant effect of selenium supplementation on platelet GPx activity (WMD: 69.4 U/g protein; 95% CI: 12.6, 126.2; 4 studies; 93 participants; P heterogeneity ¼ 0.0002; I 2 : 85%) ( Figure 5B ), but there were too few studies to use subgrouping to attempt to explain the heterogeneity. Three supplementation studies assessed erythrocyte GPx activity, which included 42 participants, with between 3 (36) and 10 participants per arm (17, 39) . Pooling the 3 studies did not provide sufficient participants to be clear on whether there was a significant effect of selenium supplementation on erythrocyte GPx activity (WMD: 3.37 lmol, NADPH oxidized Á min 21 Á g hemoglobin 21 ; 95% CI: 20.99, 7.74; 3 studies; 42 participants; P heterogeneity ¼ 0.0006; I 2 : 87%) ( Figure 5C ), and there were too few studies to use subgrouping. One supplementation study assessed muscle GPx activity (43) and included 21 participants. There was insufficient evidence in this study to assess whether muscle GPx activity is a useful marker of selenium status (Table 4) .
Four studies, including 73 participants with between 2 (41) and 18 participants per arm, assessed whole-blood GPx activity (35) . Participants of 3 studies were healthy volunteers, and the other study included participants chosen for being from a low-s elenium-status population in New Zealand. Meta-analysis suggested a statistically significant effect of supplementation on whole-blood GPx activity (WMD: 3.18 U/g hemoglobin; 95% CI: 0.07, 6.29; 4 studies; 73 participants; P heterogeneity ¼ 0.0001; I 2 : 86%) ( Figure 5D ), but again there were insufficient numbers of studies for subgrouping to be usefully employed to explore the sources of the heterogeneity.
Selenoprotein P
Three supplementation studies, all randomized controlled trials (RCTs), assessed plasma selenoprotein P (15, 31, 32) and included 68 participants with between 6 (15) and 19 participants per arm (32) . Two studies included healthy volunteers, and one included farmers from a Keshan endemic area in China. Pooling the 3 RCTs suggested a statistically significant effect of selenium supplementation on selenoprotein P (WMD: 2.19 lg/ mL; 95% CI: 0.25, 4.12; 68 participants; P heterogeneity , 0.00001; I 2 : 95%) ( Figure 6) ; however, there were insufficient studies to explore the reasons for heterogeneity.
Other biomarkers
The review identified 3 additional biomarkers, namely plasma triiodothyroxine:thyroxine ratio (T3:T4), plasma thyroxine, and plasma total homocysteine, but in each case the data were limited. Meta-analysis of 2 randomized supplementation studies assessing plasma T3:T4 (44, 46) did not suggest a statistically significant effect of selenium supplementation on this biomarker (WMD: 0.00095; 95% CI: 20.00178, 0.00369; 227 participants; P heterogeneity ¼ 0.15; I 2 : 53%). Only one RCT assessed plasma thyroxine (31) , but the results did not suggest a statistically significant effect of selenium on plasma thyroxine (210.0 nmol/L; 95% CI: 231.7, 11.7; 21 participants). Plasma total homocysteine was also evaluated in only one study (46) , but again there was no suggestion from this large trial of a significant effect of selenium supplementation on this potential indicator of status (0.30 lmol/L; 95% CI: 20.37, 0.97; 167 participants). Consequently, it was not possible to draw any firm conclusions about the effectiveness of these biomarkers because of insufficient numbers of subjects and available studies.
DISCUSSION
The data from the 18 studies of selenium supplementation included in this systematic review suggest that plasma, erythrocyte, and whole-blood selenium, plasma selenoprotein P, and plasma, platelet, and whole-blood GPx activity are all likely to be useful markers of selenium status. There was insufficient evidence for other potential biomarkers of selenium status, including urinary selenium, plasma T3:T4 ratio, plasma thyroxine, or plasma total homocysteine, erythrocyte, and muscle GPx activity (Table 3) . It was not possible to draw any meaningful conclusion from subgroup analysis by type of study, age, sex, BMI, etc, for all the biomarkers except plasma selenium (Table 4) because of the paucity of the data available.
One observation derived from the forest plots of the selenium biomarkers is that results from some studies show significant responses to change in selenium intake, whereas others do not. Although we tried to use subgrouping to help determine when the biomarkers were responsive, this was rarely useful due to limited data. For this reason it is important that further research is undertaken to define the circumstances under which particular biomarkers can be used. It is likely that the response to a change in selenium intake in some biomarkers is dependent on the baseline level, ie, on whether or not the marker is on the doseresponse plateau at the start of the intervention. Plasma selenium is an exception in that a response is observed regardless of the baseline concentration (see further discussion below).
Despite our best efforts in using a rigorous and systematic methodology to undertake this review, the outcomes are somewhat limited because of problems with gaining accurate data from the included studies (see Methods) and a lack of data from studies with a low risk of bias. Ideally, all included studies would have been RCTs and would have provided clearly tabulated data. We did consider conducting a sensitivity analysis, removing data where we had to make assumptions or measure from graphs, but this would have left us with few remaining studies. Similarly, there was only one RCT considered to be at low risk of bias. The lack of consistency between the units used for the same measurements (eg, urinary selenium measured either in micromoles per day or in micromoles per gram creatinine) also meant that many results could not be combined in the analysis, weakening the overall results. We therefore recommend that universal units should be agreed upon among experts, on the basis of the accuracy of each measurement, and adopted for future research studies. Finally, because we confined our search to studies published before September 2007, relevant, and potentially important, studies published afterward were not included in our analysis (47-50). , and (D) whole-blood (U/g hemoglobin) glutathione peroxidase activity response to selenium supplementation. RCT, randomized controlled trials; CCT, nonrandomized controlled trials; WMD, weighted mean difference.
would also be useful in assessing status in depleted individuals, but unfortunately we were unable to confirm this due to the lack of suitable studies. Additionally, this review highlights the usefulness of erythrocyte and whole-blood selenium as markers of selenium status, both of which are reported to be markers of long-term status (52) .
According to our analysis, plasma, platelet, and whole-blood GPx activity reflected the intake of selenium, but there were insufficient data to be clear about erythrocyte or muscle GPx activity. Although our analysis assessed the effect of selenium supplementation on total GPx activity, there are reports in the literature referring to the use of specific members of the GPx family in platelets as biomarkers of selenium status. Platelet GPx1 and GPx4 activities are believed to be an accurate reflection of selenium status (17, 48, 53, 54) , although the response of GPx1 activity in platelets reaches a plateau when plasma selenium is relatively low, namely 100 ng/mL (27, 54) , and so use of platelet GPx activity as a biomarker of status is potentially limited to populations with low-selenium status at baseline.
We were unable to draw any firm conclusions from our analysis about the usefulness of urinary selenium plasma T3:T4, plasma thyroxine, or plasma total homocysteine as a valid biomarker of selenium status due to the lack of data. It is unlikely that plasma T3:T4, plasma thyroxine, or plasma total homocysteine would be reliable specific biomarkers of selenium status because concentrations of these 3 biomarkers can be altered by other dietary constituents and factors. For example, plasma homocysteine can be altered by folate and vitamin B-12 status (55) and plasma T3:T4 and thyroxine can be altered by iodine intake, certain drugs, and various diseases (56, 57) . In addition, 2 independent studies published since our search was run have demonstrated that an increase in selenium intake (100-300 lg/d as selenium-enriched yeast) did not alter the plasma T3:T4 ratio significantly (49) or serum thyroxine or T3 concentrations (50) . Urinary selenium has also been shown to be a reliable marker for recent intake of selenium (48) rather than a robust biomarker for selenium status.
Selenoprotein P accounts for 50% of selenium in the blood and was found to be a useful biomarker in the meta-analysis undertaken for this review. Other reports confirm that it is a relatively reliable biomarker in populations with relatively low-to-moderate selenium intakes (31, 58) but not in populations with high intakes that were selenium replete before supplementation was begun (15) .
As investigators continue to search for the ideal selenium biomarker that is both specific and sensitive, molecular biology techniques are being used in an attempt to develop novel indicators of selenium status. For example, selenoprotein W and GPx1 mRNA concentrations seem to be sensitive markers of selenium status in animal models (59, 60) . However, in humans, within a relatively small range of selenium intake, mRNA concentrations of the selenoproteins W, H, and P and GPx 1, 3, and 4 do not correlate significantly with plasma selenium concentration (61) . Nevertheless, other candidate molecular markers may be useful indicators of selenium status in relation to intake of different forms of selenium. Supplementation of healthy volunteers with sodium selenite (100 lg/d) significantly increased the expression of several genes encoding ribosomal proteins L30, L37A, and eukaryotic translation elongation factor 1 epsilon 1 (62) . However, the use of these selenium-responsive genes awaits further validation especially due to the relatively small change in gene expression (,1.5-fold increase) quantified after selenium supplementation. A good candidate molecular marker ideally would require more pronounced effects of selenium supplementation on selenium-responsive gene expression before a significant difference could be detected at a population level or among groups with differing selenium status because of interindividual variation and the effect of single nucleotide polymorphisms, which can alter the responsiveness of several selenoprotein biomarkers (63, 64) . Unfortunately, because of the novelty of this research and the lack of data, none of these novel biomarkers could be examined in this systematic review, but the development of functional markers of selenium status is clearly a high priority.
Most of the data relate to plasma selenium, but more large, high-quality RCTs are needed for all of the potentially sensitive and useful biomarkers, particularly the most promising newer biomarkers such as selenoprotein P, to explore the reasons for the heterogeneity in response to selenium supplementation. Also, for all potential biomarkers, more information is needed to understand the limitations of applicability for different population groups, the possible effects of genotype, supplementation doses, duration, baseline status, etc. Ideally, this information would be obtained from large and well-conducted RCTs with a variety of selenium doses and undertaken over periods of several months and where initial selenium status is well defined. Use of a wide range of potential biomarkers in each study would allow us to understand the effectiveness of each biomarker for individuals and populations and to compare the relative sensitivity of biomarkers. Data in published studies need to be clearly presented in tabular form and with unambiguous information on the numbers of participants at each point and relevant variance data, together with detailed methods of analysis and universally accepted units FIGURE 6 . Plasma selenoprotein P response to selenium supplementation (lg/mL). RCT, randomized controlled trials; WMD, weighted mean difference.
of enzyme activity or protein concentration. Eventually, the results of such studies will lead to the development of evidencebased dietary recommendations specific to all subgroups of the population, which to date has not been feasible. (Other articles in this supplement to the Journal include references 18, 55, and 65-70.) 
